UroGen Pharma (URGN) said Tuesday it has reached a settlement and licensing agreement with Teva Pharmaceutical (TEVA) resolving patent litigation related to Teva's proposed generic version of Jelmyto, the company's treatment for low-grade upper tract urothelial cancer.
Under the agreement, UroGen said it will grant Teva a non-exclusive license to market a generic version of Jelmyto starting Sept. 15, 2030, subject to FDA approval.
The companies will also seek dismissal of the ongoing patent lawsuit with prejudice, according to a statement.
Financial terms of the settlement and license agreement were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments